RESUMO
BACKGROUND: Human CD4+CD25+FOXP3+ natural regulatory T-cells (nTreg) have a great therapeutic potential for the induction of tolerance in allo-transplanted patients or for the control of severe auto-immune diseases. However, clinical-grade production of nTreg remains difficult to achieve because of the absence of a truly specific surface marker and of their low frequency that implies a need for their ex vivo expansion. Furthermore, safety issues should be taken into consideration due to the risk of either uncontrolled nTreg-induced immunosuppression or uncontrolled proliferation of autoreactive contaminating T-cells particularly in an auto-immune context. METHODS: We compared different clinical-grade conditions for immuno-magnetic selection and ex vivo expansion of nTreg. For safety, expanded cells were genetically modified with retroviral vectors co-expressing human CD90 and HSV1 thymidine kinase. The CD90 surface marker and thymidine kinase allow for selection and elimination of transduced cells by ganciclovir, respectively. RESULTS: We showed that (i) nTreg could be enriched in a one step using CD25 microbeads, were functionally suppressive and mainly FOXP3+; (ii) using anti-CD28- and anti-CD3-coated beads, interleukin-2 and rapamycin, nTreg were expanded 150-200-fold after 3 weeks. Under these clinical-grade conditions, they remained suppressive, and no major alteration of the TCR repertoire was observed; (iii) after efficient retroviral transduction and CD90 selection, nTreg maintained their suppressive activity; (iv) transduced nTreg could be eliminated by ganciclovir upon activation. CONCLUSIONS: The efficient procedure reported here for the preparation of nTreg, whose safety has been ensured, is now applicable for further clinical trials.
Assuntos
Genes Transgênicos Suicidas/genética , Retroviridae/genética , Linfócitos T Reguladores/imunologia , Antígenos Thy-1/genética , Timidina Quinase/genética , Anticorpos Monoclonais/imunologia , Linfócitos T CD4-Positivos/imunologia , Morte Celular/genética , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Fatores de Transcrição Forkhead/metabolismo , Ganciclovir/farmacologia , Vetores Genéticos , Herpesvirus Humano 1/enzimologia , Humanos , Separação Imunomagnética , Imunossupressores/farmacologia , Interleucina-2/farmacologia , Subunidade alfa de Receptor de Interleucina-2/metabolismo , Subunidade alfa de Receptor de Interleucina-7/metabolismo , Ativação Linfocitária/efeitos dos fármacos , Microesferas , Sirolimo/farmacologia , Linfócitos T Reguladores/efeitos dos fármacos , Fatores de Tempo , Transdução GenéticaAssuntos
Genes Transgênicos Suicidas , Linfócitos T Reguladores/citologia , Linfócitos T Reguladores/enzimologia , Timidina Quinase/genética , Proliferação de Células/efeitos dos fármacos , Separação Celular , Humanos , Magnetismo , Sirolimo/farmacologia , Linfócitos T Reguladores/efeitos dos fármacosRESUMO
Polymyositis is a CD8(+) T-cell-mediated disease. T-cell clonal expansions are observed at disease onset, but little is known about their persistence over time. Qualitative and quantitative spectratyping demonstrated that PM relapse features dramatically perturbed blood T-cell repertoires but is not associated with the emergence of new T-cell clones. It is striking that patients in remission also maintained all their T-cell repertoire abnormalities. The clonally expanded T-cells displayed a memory phenotype, expressed intracellular perforin, and dramatically responded to IL-2, showing a potential to be reactivated upon appropriate conditions. These results indicate that persistent T-cell clonal expansion is an important feature of polymyositis.
Assuntos
Polimiosite/imunologia , Polimiosite/patologia , Linfócitos T/imunologia , Linfócitos T/patologia , Proliferação de Células , Células Cultivadas , Células Clonais , Humanos , Ativação Linfocitária , Polimiosite/genética , Fatores de TempoRESUMO
BACKGROUND/AIMS: Patients with hepatitis C virus (HCV) mixed cryoglobulinemia (MC) vasculitis have a higher mortality rate and more frequent incidence of cirrhosis than their cryoglobulin-negative counterparts. To compare the cytokine profile of liver-infiltrating T cells in HCV-infected patients with or without MC vasculitis. METHODS: Hepatic biopsy specimens were obtained from HCV infected patients with and without MC vasculitis. Using intracellular staining and flow cytometry, we assessed the ability of freshly isolated liver T cells from these biopsies to produce IFN-gamma, TNF-alpha, IL-2, IL-4, and IL-10 in response to stimulation with PMA and ionomycin. RESULTS: HCV-MC vasculitis patients compared to HCV-MC negative controls have an enhanced hepatic T cells production of Th1-type cytokines [i.e. TNF-alpha(30.3 +/- 13% vs. 15.5 +/- 5%, P = 0.01), IL-2 (20.2 +/- 9% vs. 10 +/- 4%, P = 0.01) and IFN-gamma (22.2 +/- 11% vs. 9.4 +/- 4%, P = 0.008)], whereas IL-10, a representative Th2-type cytokine, was significantly lower (7.2 +/- 4% vs. 17 +/- 7%, P = 0.01). CONCLUSIONS: T cell from the liver of HCV-MC vasculitis patients display a significantly augmented liver Th1 profile compared to MC-negative controls. This enhanced production of type-1 cytokines may account for a more severe course of liver disease.